Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold

DSpace/Manakin Repository

Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold

Citable link to this page

 

 
Title: Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold
Author: Roux, Jérémie; Hafner, Marc; Bandara, Samuel; Sims, Joshua J; Hudson, Hannah; Chai, Diana; Sorger, Peter K

Note: Order does not necessarily reflect citation order of authors.

Citation: Roux, Jérémie, Marc Hafner, Samuel Bandara, Joshua J Sims, Hannah Hudson, Diana Chai, and Peter K Sorger. 2015. “Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold.” Molecular Systems Biology 11 (5): 803. doi:10.15252/msb.20145584. http://dx.doi.org/10.15252/msb.20145584.
Full Text & Related Files:
Abstract: When cells are exposed to death ligands such as TRAIL, a fraction undergoes apoptosis and a fraction survives; if surviving cells are re-exposed to TRAIL, fractional killing is once again observed. Therapeutic antibodies directed against TRAIL receptors also cause fractional killing, even at saturating concentrations, limiting their effectiveness. Fractional killing arises from cell-to-cell fluctuations in protein levels (extrinsic noise), but how this results in a clean bifurcation between life and death remains unclear. In this paper, we identify a threshold in the rate and timing of initiator caspase activation that distinguishes cells that live from those that die; by mapping this threshold, we can predict fractional killing of cells exposed to natural and synthetic agonists alone or in combination with sensitizing drugs such as bortezomib. A phenomenological model of the threshold also quantifies the contributions of two resistance genes (c-FLIP and Bcl-2), providing new insight into the control of cell fate by opposing pro-death and pro-survival proteins and suggesting new criteria for evaluating the efficacy of therapeutic TRAIL receptor agonists.
Published Version: doi:10.15252/msb.20145584
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461398/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295697
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters